After a three-year trial, Medtronic is touting positive results for the EverFlex self-expanding stent for treating peripheral artery disease it acquired when it bought Covidien for $50 billion, according to  “The global medical device giant said 3-year results from the Durability II study of Everflex showed the single-stent treatment had sustained effect in addressing long, complex lesions in the superficial femoral and popliteal arteries and keeping them unobstructed.”  For more information on the results, please visit: